Treatment News : Study on Intermittent Dosing of PrEP Suggests High Adherence

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 28, 2014

Study on Intermittent Dosing of PrEP Suggests High Adherence

AIDS 2014Preliminary results from the pilot phase of a study of an intermittent dosing strategy for Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) have suggest that a high proportion of the participants are adhering well, aidsmap reports. Researchers from the French IPERGAY study, which recruited 153 men who have sex with men (MSM) to receive Truvada or a placebo, presented their findings at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia. Full trial results are expected in late 2016.

Colloquial French often uses the prefix “hyper-,” pronounced “eeper,” as a superlative. In the French alphabet, the letter “i” is pronounced like an English “e.” So spoken out loud, “IPERGAY” translates to “really gay.”

In a structured take on what has been called “disco dosing,” the researchers instructed the participants to take two PrEP pills two to 24 hours before sex and another 24 hours later and yet another 24 hours after that. The participants were prescribed enough Truvada to take the drug daily.

The men reported a median two acts of anal intercourse per week and an average of 10 partners in two months.

The investigators studied the adherence of the first 129 men to be randomized between February 2012 and February 2013. Fifty-three percent reported in a self-interview that they were taking all the doses according to schedule. During quarterly in-person interviews, 76 percent of them said they had taken PrEP the last time they had sex, with 11 percent reporting taking Truvada “often.” Pill counts showed that participants were taking about 15 Truvada per month. Four men reported taking the drug daily.

Blood plasma tests showed that between 82 percent and 91 percent of the participants had tenofovir in their blood and 75 percent to 84 percent had emtricitabine—the two antiretrovirals (ARV) in Truvada. The test can detect the medications in the blood for up to seven days after they are taken, so this suggests that about 80 to 85 percent of the men had taken Truvada within a week of being tested.

In the placebo arm, 4 percent to 6 percent had detectable levels of both drugs. Half had taken post-exposure prophylaxis (PEP), which includes Truvada along with another ARV. (The study permitted this.) The researchers speculate that others in the placebo group may have taken Truvada “informally.”

To read the aidsmap story, click here.

To read the conference abstract, click here.

To read a POZ feature article about circumcision in Africa and skepticism surrounding the public health effort in this regard, click here.

Search: PrEP, pre-exposure prophylaxis, Truvada, tenofovir, emtricitabine, IPERGAY, AIDS 2014, 20th International AIDS Conference, intermittent dosing, disco dosing, adherence.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    july8th69
    brooklyn
    New York


    cortaza100
    Oakland
    California


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.